Bayer IR Newsfeed: Events

19.11.09: Positive Results from Chronic Study with Bayer's Rivaroxaban Will be Presented As a Late Breaker at ASH 2009

ir@bayer-ag.de — Thu, 19 Nov 2009 15:10:03 +0100

Positive Results from Chronic Study with Bayer's Rivaroxaban Will be Presented As a Late Breaker at ASH 2009

Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE

mehr ...

02.11.09: Successful purchase of trait platform with extensive product pipeline:

ir@bayer-ag.de — Mon, 2 Nov 2009 14:35:04 +0100

Bayer CropScience completes acquisition of biotech company Athenix Corp.

Purchase price of USD 365 million plus milestones

mehr ...

27.10.09: Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:

ir@bayer-ag.de — Tue, 27 Oct 2009 06:35:04 +0100

Bayer back on the uptrend

HealthCare again strong - weak quarter at CropScience - MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed

mehr ...

23.10.09: Bayer and Onyx Initiate Phase III Trial of Nexavar� in Patients with Non-Responsive Thyroid Cancer

ir@bayer-ag.de — Fri, 23 Oct 2009 06:35:03 +0200

Bayer and Onyx Initiate Phase III Trial of Nexavar� in Patients with Non-Responsive Thyroid Cancer

mehr ...

22.10.09: Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:

ir@bayer-ag.de — Thu, 22 Oct 2009 14:00:07 +0200

The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market

mehr ...

09.10.09: Improvement in orders

ir@bayer-ag.de — Fri, 9 Oct 2009 17:05:02 +0200

Bayer MaterialScience AG ends reduced working hours at German sites

Rates of pay to be raised again / Solidarity-based solution has proved its worth / Opening clause in collective agreement applied from February to the end of October 2009

mehr ...

05.10.09: Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):

ir@bayer-ag.de — Mon, 5 Oct 2009 16:00:05 +0200

Bayer's novel oral contraceptive Qlaira� significantly reduces heavy menstrual bleeding

Results also confirm significant improvement in blood iron levels

mehr ...

30.09.09: Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer

ir@bayer-ag.de — Wed, 30 Sep 2009 06:00:04 +0200

Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer

Preliminary results require further analysis and interpretation

mehr ...

23.09.09: Phase II Study in Advanced Breast Cancer:

ir@bayer-ag.de — Wed, 23 Sep 2009 10:35:04 +0200

Nexavar� in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival

First presentation of results at joint ECCO-ESMO congress in Berlin, Germany

mehr ...

22.09.09: Results of a Phase II study in Renal Cell Carcinoma (RCC):

ir@bayer-ag.de — Tue, 22 Sep 2009 07:05:03 +0200

Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients

Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009

mehr ...

17.09.09: Greater focus on future technologies:

ir@bayer-ag.de — Thu, 17 Sep 2009 08:35:03 +0200

Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018

BioScience sales of EUR 1.4 billion targeted for 2018 / Biotech licensing agreements tap into business potential in excess of EUR 500 million / Peak sales potential of new crop protection actives raised to EUR 1.25 billion

mehr ...

17.09.09: Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:

ir@bayer-ag.de — Thu, 17 Sep 2009 06:35:03 +0200

Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009

Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions

mehr ...

15.09.09: Bayer Supervisory Board decides company's future management line-up:

ir@bayer-ag.de — Tue, 15 Sep 2009 09:30:04 +0200

Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010

Werner Wenning extends his contract by eight months / CFO Klaus K�hn to retire on April 30, 2010 / Werner Baumann to be new CFO / BHC CEO Arthur J. Higgins to leave Bayer at his own request

mehr ...

03.09.09: Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients

ir@bayer-ag.de — Thu, 3 Sep 2009 06:05:03 +0200

Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients

Phase III compound represents potential therapy for life-threatening condition

mehr ...

02.09.09: Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.

ir@bayer-ag.de — Wed, 2 Sep 2009 16:05:03 +0200

Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.

Bayer subsidiary Intendis expands presence in the U.S. / Asset purchase agreement signed for marketed prescription products Desonate� and NeoBenz� Micro

mehr ...